Brokerages Set Celcuity, Inc. (NASDAQ:CELC) Price Target at $28.40

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have received a consensus rating of "Buy" from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $28.40.

A number of research analysts have weighed in on CELC shares. HC Wainwright restated a "buy" rating and issued a $27.00 price target on shares of Celcuity in a research note on Monday, May 19th. Stifel Nicolaus began coverage on Celcuity in a report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $29.00 target price on shares of Celcuity in a report on Monday, June 30th.

Celcuity Stock Up 0.8%

NASDAQ:CELC traded up $0.11 during trading hours on Tuesday, reaching $13.51. 244,660 shares of the stock were exchanged, compared to its average volume of 276,327. The stock has a market cap of $511.57 million, a PE ratio of -4.46 and a beta of 0.45. Celcuity has a twelve month low of $7.58 and a twelve month high of $19.77. The firm has a 50 day moving average of $11.65 and a 200 day moving average of $11.29. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.61 and a quick ratio of 6.61.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.09. On average, equities analysts expect that Celcuity will post -2.62 earnings per share for the current year.

Institutional Trading of Celcuity

Hedge funds and other institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP grew its holdings in Celcuity by 59.0% in the 1st quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company's stock valued at $43,046,000 after buying an additional 1,579,182 shares in the last quarter. Soleus Capital Management L.P. grew its stake in shares of Celcuity by 106.0% in the fourth quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company's stock valued at $33,577,000 after acquiring an additional 1,319,700 shares in the last quarter. Vanguard Group Inc. increased its position in Celcuity by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock worth $21,624,000 after acquiring an additional 24,429 shares during the period. Geode Capital Management LLC raised its stake in Celcuity by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 692,372 shares of the company's stock worth $9,065,000 after purchasing an additional 62,003 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in Celcuity in the 4th quarter worth about $8,468,000. Institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.